$WEED.TO

Canopy Growth Q4 Net Loss Narrows, Net Revenue Advances, But Both Miss Forecasts

Canopy Growth (WEED.TO), down 2.1% in U.S. pre-market trading, said on Monday that fourth quarter net loss narrowed as net revenue increased, but both fell short of analyst expectations.Net loss from continuing operations improved to $154.7 million, or $0.40 loss per share, from a net loss of $196 million, or $1.27 loss per share, for the prior year period. The result missed the consensus analyst estimate of a loss of $0.10 per share, according to FactSet.Net revenue advanced from $65 million to $71.2 million, but missed the $74.3 million forecast. Cannabis net revenue jumped 20% to $54.5 million during the quarter. International markets cannabis net revenue of $8.6 million was a 60% increase year over year, due to a smoothing out of supply chain challenges in Europe earlier in the fiscal year.Canopy Growth shares were last seen down US$0.02, to US$0.98, in New York trading.

Earnings Flash (WEED.TO) Canopy Growth Net Loss From Continuing Ops in Q4 FY2026 Was 21% Lower Xompared to Q4 FY2025

Canopy Growth Reports Consolidated Net Revenue of $71.2M in Q4 FY2026

Canopy Growth Relaunches Tweed Brand in Germany With New MTL Cannabis Strain Lineup

Canopy Growth (WEED.TO, CGC) relaunched Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by its unit MTL Cannabis (MTL), it said on Friday.The initial launch includes "Pablo's Revenge, Dante'z Inferno, and Frost'd Flakes" cultivars. Up to five MTL-derived strains are expected to be introduced in June 2026, with further portfolio expansion planned throughout the year, it said.The company also announced that it has been granted a management cease trade order effective as of May 28, by its principal regulator, the Ontario Securities Commission, following its announcement on May 15, regarding certain non-cash technical errors in its accounting. Canopy Growth intends to refile the relevant financial statements in its Annual Report on Form 10-K for the fiscal year ended March 31, 2026, it said.U.S.-listed shares of the company were last seen unchanged at US$1.12 in pre-market trading.

Canopy Growth Adds "No Impact on Core Operating Performance"

Canopy Growth Says During YE Financial Reporting Process For Fiscal Year Ended March 31, 2026, the Co Identified a Technical Non-cash Accounting Error

Canopy Growth Also Plans to File Restated Financials for Fiscal Years Ended March 31, 2025 and March 31, 2024 and Certain Interim Periods

Canopy Growth Expects to Release Financial Results for Quarter and Fiscal Year Ended March 31, 2026, Before Markets Open on June 15, 2026

Canopy Growth and Spectrum Therapeutics Expanding Medical Portfolio With New 30 And 90-Pack Softgels and Enhanced Dosing Options